| 摘要 |
This invention is generally directed to methods for treating or preventing acute myelogenous leukemia ("AML") comprising administering to a patient in need thereof an effective amount of an Indazole Compound having the structur e: or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisom er or enantiomer thereof, wherein R1, R2 and A are as defined herein.
|
